Melrilimab

迈瑞利单抗

Report date: 2024/05/15 20:00:35

Base Information

Drug NameMelrilimab
Drug Alias NameGSK-3772847CNTO-7160
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-1 receptor-like 1 inhibitors
TargetsInterleukin-1 receptor-like 1
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A